Table 2.
Performance indicators of various gametocytocidal assay platforms
| Assay performance parameters (avg) | ATP | pLDH | PrestoBlue® | Luciferase |
|---|---|---|---|---|
| (n = 4) | (n = 4) | (n = 4) | (n = 4) | |
| S/N | >15 000 | >300 | >900 | 16 000 (early) |
| 500 (late) | ||||
| S/B | 500 | 3.2 | 15 | 175 |
| Z’-factor (avg) | 0.79 | 0.87 | 0.91 | 0.81 |
| %CV (intra-assay) | 8.8 % | 2.4 % | 3.15 % | 0.73 % |
| Avg DHA activity at 1 μM (% inhibition) | 37.19 ± 7.67 % | 62 ± 6 % | 83.48 ± 8.58 % | 73.56 ± 5.58 % (avg early/late) |
| IC50 DHA | 14.9 μMa | 20 nM | 11 nM | 43 nM (early) |
| 11 nM (late) | ||||
| IC50 MB | 900 nMa | 800 nM | - | 195 nM (early) |
| 143 nM (late) |
DHA Dihydroartemisinin, MB Methylene blue
aunpaired experiments at 24 h
Each assay was performed after 48 h drug exposure and comparative quality control parameters determined, utilising standardization of DHA activity as common factor between all the assay platforms. Methylene blue interferes with the PrestoBlue® assay and was not used as control. Data are from 4 independent experiments (performed in triplicate) for each assay platform